0001209191-18-058508.txt : 20181114 0001209191-18-058508.hdr.sgml : 20181114 20181114161012 ACCESSION NUMBER: 0001209191-18-058508 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20181109 FILED AS OF DATE: 20181114 DATE AS OF CHANGE: 20181114 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Walsh Jeffrey T. CENTRAL INDEX KEY: 0001578251 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35966 FILM NUMBER: 181183790 MAIL ADDRESS: STREET 1: C/O BLUEBIRD BIO, INC. STREET 2: 840 MEMORIAL DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: bluebird bio, Inc. CENTRAL INDEX KEY: 0001293971 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 60 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 339-499-9300 MAIL ADDRESS: STREET 1: 60 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Genetix Pharmaceuticals Inc DATE OF NAME CHANGE: 20040616 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-11-09 0 0001293971 bluebird bio, Inc. BLUE 0001578251 Walsh Jeffrey T. C/O BLUEBIRD BIO, INC. 60 BINNEY STREET CAMBRIDGE MA 02142 0 1 0 1 Chief Financial and Strategy Officer Common Stock 2018-11-09 4 M 0 1500 24.47 A 36995 D Common Stock 2018-11-09 4 S 0 320 129.1225 D 36675 D Common Stock 2018-11-09 4 S 0 700 130.6129 D 35975 D Common Stock 2018-11-09 4 S 0 480 131.5465 D 35495 D Stock Option (right to buy) 24.47 2018-11-09 4 M 0 1500 0.00 D 2024-03-03 Common Stock 1500 20521 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 2, 2018. The range of prices for the transaction reported on this line was $128.90 to $129.61. The average weighted price was $129.1225. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for the transaction reported on this line was $130.10 to $131.06. The average weighted price was $130.6129. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for the transaction reported on this line was $131.46 to $131.625. The average weighted price was $131.5465. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. This option vested over a four-year period, at a rate of twenty-five percent (25%) on January 1, 2015 and in 36 equal monthly installments thereafter. /s/ Jason F. Cole, Attorney-in-Fact 2018-11-14